1. Germany Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Merck KGaA

Merck KGaA

145.60
EUR
+3.25
(+2.28%)
5.86EPS
18.55P/E
46.98BMarket Cap
Nov 12Next Earn
Merck KGaA
STU:MRK
(Stuttgart Stock Exchange)

Recent

price

145.60

P/E

ratio

18.55

div

yld

0.47%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
EUR
21.37
23.64
25.73
25.56
26.12
29.49
34.59
33.38
34.12
37.15
40.33
45.28
51.13
48.28
48.66
48.54
- -
Revenue per Share
1.48
1.4
1.3
2.77
2.66
2.56
3.75
5.99
7.76
3.04
4.57
7.03
7.65
6.5
6.39
6
- -
Basic EPS, GAAP
2.95
1.9
4.6
3.94
4.78
3.45
3.84
3.18
2.77
4.22
4.4
7.35
5.64
4.05
5.52
4.54
- -
Free Cash Flow per Basic Share
0.2
0.2
0.98
0.95
1.16
1.29
1.37
1.43
0.37
0.37
0.39
0.42
0.55
0.65
0.65
0.65
0.03
Dividend per Share
23.77
24.03
23.83
25.35
27.01
29.41
32.18
32.21
39.56
41.03
38.98
49.08
59.63
61.36
68.8
65.76
- -
Book Value per Share
-4.94
-3.03
-1.34
2.65
0.8
-29.06
-25.31
-18.17
-8.74
-19.54
-15.33
-7.54
0.47
5.25
10.25
6.89
- -
Tangible Book Value per Share
435
435
434
434
435
436
434
435
435
435
435
435
435
435
435
435
435
Basic Weighted Avg Shares
9,291
10,276
11,173
11,095
11,363
12,845
15,024
14,517
14,836
16,152
17,534
19,687
22,232
20,993
21,156
21,102
- -
Sales/Revenue/Turnover
11.9
11.98
16.93
18.83
15.39
16.88
15.45
15.23
12.36
14.26
16.03
21.38
21.37
17.02
18.95
17.33
- -
Operating Margin (%)
1,258
1,597
1,397
1,458
1,361
1,511
1,934
1,758
1,812
1,944
1,938
1,767
2,030
1,880
2,134
2,298
- -
Depreciation Expense
642
607
567
1,202
1,157
1,115
1,629
2,605
3,374
1,320
1,987
3,055
3,326
2,824
2,777
2,608
- -
Net Income, GAAP
25.5
26.32
18.34
12.93
25.19
24.75
24.19
- -
25.19
25.36
24.22
21.89
22.11
18.66
21.24
20.95
- -
Effective Tax Rate (%)
6.9
5.9
5.07
10.84
10.18
8.68
10.84
17.94
22.74
8.17
11.33
15.52
14.96
13.45
13.13
12.36
- -
Profit Margin (%)
2,306
2,037
2,065
3,486
3,879
-2,040
-1,419
-1,180
719
-2,839
49
550
2,687
3,694
2,155
4,188
- -
Working Capital
5,127
3,989
3,362
3,258
3,444
9,513
8,705
7,946
6,681
8,587
9,745
8,270
9,200
9,239
6,998
10,731
- -
LT Debt
10,377
10,494
10,415
11,069
11,801
12,855
14,050
14,066
17,233
17,914
17,017
21,416
26,005
26,755
29,989
28,660
- -
Total Equity
6.35
5.16
5.03
9.25
7.91
6.1
6.92
- -
4.89
5.29
7.15
10.12
9.69
7.69
7.16
6.76
- -
Return on Invested Capital (%)
4.98
5.24
5.22
9.52
8.21
6.27
7.12
- -
14.12
5.85
7.57
10.64
10.19
8.42
7.8
7.19
- -
Return on Capital (%)
6.48
5.84
5.45
11.25
10.17
9.09
12.17
18.61
21.63
7.53
11.42
15.96
14.07
10.74
9.81
8.92
- -
Return on Common Equity (%)

Capital Structure

EUR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,221
1,236
- -
LT Borrowings
10,206
- -
- -
LT Finance Leases
525
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
435
435
129
Market Capitalization
53,173
46,978
18,915

Working Capital

EUR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
13,230
14,162
- -
Cash, Cash Equivalents & STI
2,925
3,774
- -
Accounts Receivable, Net
3,947
4,318
- -
Inventories
4,562
4,782
- -
Total Current Liabilities
9,042
9,349
- -
Payables & Accruals
- -
- -
- -
ST Debt
1,221
1,236
- -
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.87%
11.56%
-4.43%
Free Cash Flow
7.19%
6.82%
-17.82%
Net Income, GAAP
16.5%
7.96%
-6.09%
Sales/Revenue/Turnover
5.34%
4.03%
-0.26%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,120
5,352
5,266
5,418
21,156
2025
5,280
5,255
5,318
5,249
21,102
2026
5,134
- -
- -
- -
- -

Quarterly Earnings Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.6
1.4
1.86
1.53
6.39
2025
1.69
1.5
2.07
0.73
6
2026
1.52
- -
- -
- -
- -

Quarterly Dividends Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.12
0.65
- -
- -
0.65
2025
0.11
0.65
- -
- -
0.65
2026
0.03
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Merck KGaA engages in the discovery, development, manufacturing, and marketing of products for healthcare, life sciences, and electronics markets worldwide. The company operates through three main business sectors: Healthcare, which offers prescription medicines for oncology, neurology, immunology, fertility, and endocrinology; Life Science, providing tools, technologies, and services for biopharmaceutical research, development, and manufacturing including process development, filtration, chromatography, and single-use systems; and Electronics, supplying materials for semiconductor, display, and surface technologies such as liquid crystals, photoresists, OLED materials, and deposition systems. Merck KGaA maintains a global presence with operations in over 60 countries, serving pharmaceutical companies, biotech firms, academic institutions, and industrial manufacturers as primary customers. Founded in 1668 and headquartered in Darmstadt, Germany, the company traces its roots as one of the world's oldest pharmaceutical and chemical firms, with subsidiaries including MilliporeSigma in the U.S. for life sciences and Versum Materials prior to its divestiture. In recent developments, Merck KGaA completed the acquisition of BioReliance in 2024 to bolster its bioprocessing services portfolio and formed a strategic alliance with Sandoz in 2025 for biosimilars co-development and commercialization in oncology; additionally, it launched the next-generation Erez™ platform for gene therapy manufacturing and expanded its electronics business through a €1.2 billion investment in a new OLED materials facility in Japan.

Company News

Company News APIChatGPT

  • wsj.com

    Germany's Merck to Buy U.K. Biotech Silence Therapeutics for $1.3 Billion

  • defenseworld.net

    Merck KGaA (OTCMKTS:MKGAF) Shares Gap Down – Should You Sell?

  • defenseworld.net

    Merck KGaA (OTCMKTS:MKKGY) versus MediciNova (NASDAQ:MNOV) Head-To-Head Contrast

  • defenseworld.net

    Merck KGaA (OTCMKTS:MKKGY) Shares Shorted: Short Interest Up 95.4% in September

  • defenseworld.net

    Merck KGaA (OTCMKTS:MKKGY) Receives Consensus Rating of “Hold” from Brokerages

  • defenseworld.net

    363,066 Shares in Merck KGaA $MKGAF Purchased by Beacon Pointe Advisors LLC

  • defenseworld.net

    Blue Edge Capital LLC Decreases Stake in Merck KGaA $MKGAF

  • defenseworld.net

    Bamco Inc. NY Buys Shares of 22,000 Merck KGaA $MKGAF

  • defenseworld.net

    ADAR1 Capital Management LLC Invests $403,000 in Merck KGaA $MKGAF

  • defenseworld.net

    Ancora Advisors LLC Invests $2.69 Million in Merck KGaA $MKGAF

  • defenseworld.net

    Ausdal Financial Partners Inc. Takes Position in Merck KGaA $MKGAF

  • defenseworld.net

    AFT Forsyth & Company Inc. Invests $822,000 in Merck KGaA $MKGAF

  • defenseworld.net

    7,331,418 Shares in Merck KGaA $MKGAF Purchased by Barrow Hanley Mewhinney & Strauss LLC

  • defenseworld.net

    Barbara Oil Co. Makes New Investment in Merck KGaA $MKGAF

  • defenseworld.net

    Ally Financial Inc. Takes $4.50 Million Position in Merck KGaA $MKGAF

  • defenseworld.net

    Emerald Investment Advisers LLC Makes New Investment in Merck KGaA $MKGAF

  • defenseworld.net

    B. Metzler seel. Sohn & Co. AG Takes Position in Merck KGaA $MKGAF

  • defenseworld.net

    Bell & Brown Wealth Advisors LLC Invests $5.66 Million in Merck KGaA $MKGAF

  • defenseworld.net

    August Group Capital Ltd Takes Position in Merck KGaA $MKGAF

  • defenseworld.net

    9,092 Shares in Merck KGaA $MKGAF Acquired by Asahi Life Asset Management CO. LTD.